Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic Cell Vaccine with Standard Radiochemotherapy in Newly Diagnosed Glioblastoma
2024-514820-18-00Phase 2Authorised
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- Mar 2018
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of autologous tumor lysate-loaded mature dendritic cell vaccine in glioblastoma (GBM), sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: Overall survival. Planned start Mar 2018; status: authorised.
02
Drugs
autologous tumor lysate-loaded mature dendritic cell vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-514820-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514820-18-00.